Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
One more addition to the GLP1-R agonist list: Injectable semaglutide previously showed MACE reduction in SUSTAIN-6. Ongoing PIONEER-6 with oral semaglutide looks to be near completion and should be reading out soon too, potentially in 2018.
